iabetes is a metabolic disorder that is diagnosed when the fasting and/or postload glucose level rises above well-established thresholds. These thresholds were chosen because they identified people at particularly high risk for retinopathy based on epidemiological data. These data also have shown that people with diabetes and poorly controlled glucose levels have higher risks of retinopathy than people with diabetes and well-controlled glucose levels. 1,2 Moreover, recent studies have shown that the relationship between chronically elevated glucose levels (as measured by A 1c ) and retinal disease is not confined to people with diabetes and is apparent (although less marked) in people with high glucose levels that are below the diabetes cutoffs such as those with impaired glucose tolerance and/or impaired fasting glucose. [3] [4] [5] Thus, there is a progressive relationship between glycemia and retinopathy that extends below glucose thresholds for diabetes.
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Clearly, diabetes also is a risk factor for many other serious chronic diseases, including cardiovascular disease. 6 Indeed, a recent meta-analysis of large prospective studies comprising 450 000 people showed that men and women with diabetes are 2 and 3 times more likely, respectively, to die of coronary heart disease than men and women without diabetes. 7 Other studies have shown that the degree of glucose elevation measured by A 1c , fasting glucose, or postload glucose is progressively related to the incidence of cardiovascular outcomes in people with established diabetes and in people without diabetes after adjustment for age and varying numbers of other risk factors. 8 -15 Moreover, several studies that recruited people from both ambulatory and hospitalized settings suggest that there may be a stronger relationship between glycemia and incident cardiovascular outcomes in people without diabetes than in people with diabetes. 8, 9, [15] [16] [17] Such a discrepancy may occur because in people with established diabetes, markers of glycemia are a measure of both adequacy of therapy and exposure to hyperglycemia, whereas they reflect only exposure to hyperglycemia in people without diabetes (in whom glucose and A 1c levels are not targets for therapy).
Retinopathy and cardiovascular disease are clearly not the only outcomes related to progressively higher glucose levels. This is perhaps best illustrated by epidemiological analyses of prospective data from the United Kingdom Prospective Diabetes Study (UKPDS), which recruited people with a fasting plasma glucose level Ͼ6 mmol/L 18 and which therefore included individuals with newly diagnosed diabetes as well as some individuals who would be classified as having impaired fasting glucose and not diabetes based on today's diagnostic criteria for diabetes (ie, fasting glucose level Ն7 mmol/L). As noted in the Figure, these analyses showed that progressively higher A 1c levels predicted progressively higher hazards of severe retinal or renal disease, cataracts, myocardial infarction, heart failure, amputation or peripheral vascular disease, stroke, and death. They also showed that the risk relationship differed with respect to outcome, with a stronger relationship to some outcomes and a weaker relationship to others (the Figure) . Thus, organ systems may vary in their susceptibility to damage related to glucometabolic abnormalities, a conclusion strongly supported by the epidemiological analysis reported in this issue of Circulation. 19 Sung et al 19 report an analysis of 652 901 Korean men 30 to 64 years of age who were followed up over a 9-year period with biannual health examinations within the Korean National Health Insurance system. They calculated average glucose levels for participants followed up during this interval of time and grouped them within clinically relevant categories. They did not analyze fasting glucose level as a continuous measure; instead, they analyzed the relationship between categories of average fasting serum glucose levels and incident myocardial infarction, ischemic stroke, and hemorrhagic stroke in 570 453 men without any missing data and reported the hazard after adjustment for age and for other cardiovascular risk factors. As reported in other studies, they found a progressive age-adjusted relationship between fasting glucose levels and both myocardial infarction and stroke that extended to normal fasting serum glucose levels. The relationship persisted with adjustment for several risk factors but was attenuated after additional adjustment for blood pressure, body mass index, and cholesterol levels. Moreover, the relationship was stronger for ischemic stroke than for either myocardial infarction or hemorrhagic stroke. Notably, their analysis detected an interaction between age and fasting glucose category in that older men had a stronger relationship between fasting glucose levels and these cardiovascular outcomes than younger men. Moreover, for stroke but not myocardial infarction, there was an interaction between body mass index and fasting glucose level category. The large number of participants and outcomes is a clear strength of this study. First, it allowed the investigators to examine the relationship between fasting glucose levels and different types of cardiovascular disease. Their observation of different relationships to myocardial infarction, ischemic stroke, and hemorrhagic stroke clearly supports the conclusion that the impact of glycemia on outcomes varies according to the outcome being assessed and extends it to different subtypes of stroke and to the general population. Second, the weaker relationship to myocardial infarction than to ischemic stroke may not have been apparent in smaller studies that did not have sufficient numbers of strokes to divide people according to the type of stroke. This finding should lead to further analyses in women and in other populations. Third, the large sample facilitated exploration of the role of confounders. The fact that adjusting for blood pressure cholesterol and body mass index attenuates the relationship between glucose and myocardial infarction to a greater extent than between glucose and ischemic stroke is interesting but unexplained. If anything, one would expect that adjustment for blood pressure would attenuate the relationship with stroke, which tends to be more strongly associated with blood pressure than myocardial infarction.
Of note, this study was conducted in relatively healthy men within the general Korean population whose 9-year incidence of myocardial infarction and stroke was quite low at 0.6% and 1.7%, respectively (ie, Ͻ0.2%/y). Its results may therefore not be directly applicable to women, to older or sicker people, or to other populations with a higher risk for cardiovascular disease. Indeed, the interaction with age in which there was a stronger relationship between fasting glucose levels Ͼ5.5 mmol/L and myocardial infarction in older versus younger people suggests that the importance of dysglycemia as a cardiovascular risk factor may be greater in people at higher risk of cardiovascular disease. It would also have been very interesting if the risk for cardiovascular outcomes across progressively higher fasting glucose levels (measured as a continuous variable) had been presented in addition to the risk across discrete categories of fasting glucose. Such an analysis would be relevant in light of the spline distribution of the data (Data Supplement Figure I in the article by Sung et al 19 ) , which is consistent with a progressive versus a threshold relationship between fasting glucose levels and both myocardial infarction and ischemic stroke.
In summary, a fasting glucose level above normal is a progressive risk factor for cardiovascular outcomes, and the magnitude of the risk rises with age and is greater for ischemic stroke than for myocardial infarction or hemorrhagic stroke. Whether specifically targeting lower fasting glucose levels can reduce cardiovascular outcomes remains unknown. Some clues may reside in the 10-year-long UK-PDS, which randomized people with newly diagnosed diabetes and few other cardiovascular risk factors to a policy of targeting a fasting plasma glucose Ͻ6 mmol/L versus a conventional policy targeting a fasting plasma glucose Ͻ15 mmol/L. 18, 20 This study reported a clear reduction in myocardial infarction and death in a subset of obese participants allocated to metformin as the means of glucose lowering, with nonsignificant cardiovascular effects in the other participants. 20 However, after 9 years of passive follow-up, all participants experienced a 13% and 15% reduction in death and myocardial infarction, respectively, and the subset given metformin retained the benefit observed during the active treatment phase. 21 Conversely, 3 large trials varying in duration from 3.5 to 6.3 years have recently reported the effect of targeting an A 1c level below 6% 22,23 or 6.5% 24 versus less intensive glucose lowering in a very different population of people with well-established diabetes (ie, of a mean duration of 8 to 12 years) and several additional cardiovascular risk factors. All 3 used a menu of drugs to lower both fasting and postprandial glucose levels and did not detect a clear cardiovascular benefit; indeed, 1 trial 22 was stopped early because of increased mortality. Taken together, these trials suggest that any benefit of glucose lowering may be greatest in people with early dysglycemia, a question that is being tested in the ongoing Outcome Reduction With an The relationship between updated A 1c and the multivariable adjusted hazard of various chronic consequences of diabetes in participants in the UKPDS based on the reported difference per 1% higher A 1c level. 1 The hazard ratio of an A 1c of 6% was set at 1.0. Line A, Amputation or death resulting from peripheral vascular disease (43% per 1%) ; B, retinal or renal disease (37% per 1%); C, cataract extraction (19% per 1%); D, heart failure (16% per 1%); E, myocardial infarction (14% per 1%) and all-cause death (14% per 1%); and F, stroke (12% per 1%). The same results are shown on a linear scale (left) and a log scale (right).
Initial Glargine Intervention (ORIGIN) clinical trial, which has randomized Ͼ12 500 people with impaired fasting glucose, impaired glucose tolerance, or early diabetes to 1 injection of insulin glargine that is titrated to a fasting plasma glucose Յ5.3 mmol/L versus standard care. 25 Data from this and other trials underway will clarify the therapeutic implications of epidemiological observations such as those published in this issue. 19 Disclosures Dr Gerstein's institution receives funding from Sanofi-Aventis to conduct the ORIGIN trial of the effect of lowering fasting glucose levels with glargine insulin on cardiovascular outcomes. Dr Gerstein holds the McMaster Population Health Research Institute Chair in Diabetes (sponsored by Aventis).
